Founded Year



Incubator/Accelerator - III | Alive

Total Raised


About Ibex Medical Analytics

Ibex Medical Analytics develops AI-driven clinical decision support tools that help pathologists deliver more efficient, metric-driven, objective and accurate diagnosis. Ibex develops a diagnostic system that uses computer vision, machine learning, and electronic medical records to confirm cancer diagnoses of tissue biopsies. The company was founded in 2016 and is based in Israel.

Ibex Medical Analytics Headquarter Location

97 Rokach Blvd

Tel Aviv, 6153101,


ESPs containing Ibex Medical Analytics

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare / Medical Devices

Computer-aided diagnostic imaging utilizes algorithms to detect, extract, and communicate data from medical images more efficiently and accurately than the human eye. The technology is being deployed across several imaging modalities to improve the detection, diagnosis, triaging, and, ultimately, the prognosis of various medical conditions.

Ibex Medical Analytics named as Leader among 15 other companies, including PathAI, Lunit, and Aidoc Medical.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Ibex Medical Analytics's Products & Differentiation

See Ibex Medical Analytics's products and how their products differentiate from alternatives and competitors

  • Galen

    Integrated dx

Research containing Ibex Medical Analytics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Ibex Medical Analytics in 2 CB Insights research briefs, most recently on Oct 7, 2021.

Expert Collections containing Ibex Medical Analytics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ibex Medical Analytics is included in 8 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

9,051 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Medical Devices

8,817 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health Monitoring & Diagnostics

2,707 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Digital Health

13,075 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Ibex Medical Analytics Patents

Ibex Medical Analytics has filed 1 patent.

The 3 most popular patent topics include:

  • Health informatics
  • Medical specialties
  • Microscopy
patents chart

Application Date

Grant Date


Related Topics



Microscopy, Pathology, Medical specialties, Speed (TV channel) shows, Health informatics


Application Date


Grant Date


Related Topics

Microscopy, Pathology, Medical specialties, Speed (TV channel) shows, Health informatics



Latest Ibex Medical Analytics News

08:00 EDT Ibex Obtains CE Mark for Galen Gastric, the World's First AI-powered Solution for Gastric Cancer Detection

Jun 15, 2022

USA - English Share this article Share this article Galen™ Gastric demonstrated outstanding outcomes in detecting gastric cancer in a multi-site study, supporting quality diagnosis, enhanced lab efficiency and quality control TEL AVIV, Israel, June 15, 2022 /PRNewswire/ --  Ibex Medical Analytics , the pioneer in AI-powered cancer diagnostics, today announced CE mark for the Galen™ Gastric solution that supports pathologists in the detection of various types of gastric cancer. With this first-of-its-kind solution becoming generally available, Ibex offers the richest portfolio of artificial intelligence (AI) solutions in pathology, enabling detection of cancer and other pathologies in gastric, breast and prostate biopsies. Gastric cancer is a prominent malignant disease in both men and women worldwide, with over a million new cases every year and a relatively poor prognosis. Pathologists play a crucial role in the detection and diagnosis of gastric cancer, with their assessments being vital for reaching correct treatment decisions by oncologists and improving patient survival rates. Over the last several years there has been an increase in overall cancer incidence, and rapid advances in personalized medicine have resulted in increases in the complexity of cancer diagnosis. Coupled with a global decline in the number of pathologists, these trends have led to growing workloads imposed on pathology departments. Clearly, there is a growing need for automated solutions and decision-support tools that help pathologists detect cancer to the utmost accuracy more rapidly, while enabling comprehensive and affordable quality control. The Galen suite of solutions is the most widely deployed AI technology in pathology, and Ibex now partners with laboratories, hospitals and health systems to implement AI for the diagnosis of gastric biopsies. Galen Gastric is an integrated diagnostics solution that supports pathologists in the detection of gastric cancer, H. pylori and other important clinical findings and in enabling shorter turnaround times and optimized diagnostic workflows1. The solution was developed by a team of pathologists, data scientists and software engineers who implemented advanced Deep Learning technologies and trained algorithms on more than a million image samples, scanned from biopsy slides digitized using digital pathology. The CE mark follows pioneering results from a blinded, multi-site clinical study at Medipath, the largest pathology network in France, and at Maccabi Healthcare Services, the second largest health network in Israel. Galen Gastric demonstrated very high accuracy in detecting various types of gastric cancer, as well as Helicobacter pylori (H. pylori - a common gastric bacterial infection and a precursor for cancer), neuroendocrine lesions, dysplasia, adenoma and additional pathologies. These results validate the robustness of Galen Gastric and support its adoption by pathology institutes that aim to improve diagnostic quality and enhance productivity. "Diagnosis of gastric biopsies remains a challenging task for pathologists. Gastric cancers are relatively scarce, often minute and sometimes easy to miss," said Judith Sandbank, MD, Director of the Pathology Institute at Maccabi Healthcare Services2, and the principal investigator in the study. "We were impressed with the successful outcomes and the very high accuracy demonstrated by Galen Gastric in detection of different cancer types. It's also encouraging to see an AI solution that goes beyond cancer detection to accurately identify H. pylori, and provide additional insights on dysplasia, lymphoma, gastritis and other pathologies. We have already started to use Galen Gastric in Maccabi and it helped us improve the quality of cancer diagnosis and patient care. I am looking forward to seeing this technology now becoming widely available at pathology departments around the world." "We are proud to obtain this first-of-its-kind CE mark for AI-powered GI diagnostics in pathology, following excellent performance in a multi-site clinical study," said Chaim Linhart, PhD, Co-founder and CTO at Ibex Medical Analytics. "We trained the Deep Learning models of Galen Gastric on more than a million image samples from multiple labs to ensure it can accurately detect not only cancer but also a multitude of other clinically relevant features that impact future treatment for patients. Ibex now offers an unprecedented breadth of clinical applications, and this approval will enable our growing customer base to expand the usage of AI technology and provide pathologists with new insights as they review gastric biopsies, improving the quality of cancer diagnosis and care." The study outcomes will be presented at the European Congress on Digital Pathology which takes place in Berlin between June 15-18 (Ibex presents at booth B11). About Ibex Medical Analytics Ibex pioneers AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis by developing clinical-grade AI algorithms and digital workflows that help detect and grade cancer in biopsies. Our Galen™ platform is the first-ever AI-powered integrated diagnostics solution in pathology and used in routine clinical practice worldwide, supporting pathologists and providers in improving the quality and accuracy of diagnosis, implementing comprehensive quality control, reducing turnaround times and boosting productivity with more efficient workflows. Ibex's Artificial Intelligence technology is built on Deep Learning algorithms trained by a team of pathologists, data scientists and software engineers. For more information, go to . Media contact:

Ibex Medical Analytics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ibex Medical Analytics Rank

  • When was Ibex Medical Analytics founded?

    Ibex Medical Analytics was founded in 2016.

  • Where is Ibex Medical Analytics's headquarters?

    Ibex Medical Analytics's headquarters is located at 97 Rokach Blvd, Tel Aviv.

  • What is Ibex Medical Analytics's latest funding round?

    Ibex Medical Analytics's latest funding round is Incubator/Accelerator - III.

  • How much did Ibex Medical Analytics raise?

    Ibex Medical Analytics raised a total of $55M.

  • Who are the investors of Ibex Medical Analytics?

    Investors of Ibex Medical Analytics include PlayBeyondBio, Dell Technologies Capital, 83North, aMoon Fund, Planven Investments and 5 more.

  • Who are Ibex Medical Analytics's competitors?

    Competitors of Ibex Medical Analytics include Aiforia, Lunit, Qritive, Stratipath, Paige and 8 more.

  • What products does Ibex Medical Analytics offer?

    Ibex Medical Analytics's products include Galen.

  • Who are Ibex Medical Analytics's customers?

    Customers of Ibex Medical Analytics include Medipath, Maccabi, CorePlus, Histopath and Kaplan.

You May Also Like


Paige delivers AI-powered digital diagnostics and biomarkers for pathologists, oncologists, and the R&D community worldwide, while also working closely with biopharma companies to create custom diagnostic solutions and drug development technologies to improve patient care. The firm's target customers include pathologists, hospital leads/chairs as well as life sciences research and translational teams.

PathAI Logo

PathAI provides AI-powered research tools and services for pathology. PathAI's platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning.

Proscia Logo

Proscia is a software company focused on transforming cancer research and diagnosis. With the company's Concentriq digital pathology platform and pipeline of AI algorithms, laboratories are leveraging new kinds of data to improve patient outcomes and accelerate discoveries. The company was founded in 2014 and is based in Philadelphia, Pennsylvania.

Deciphex Logo

Deciphex focuses on the development of software applications for preclinical/toxicologic pathology that improve productivity and help pathologists focus on the critical content. The company was founded in 2017 and is based in Dublin, Ireland.

Lunit Logo

Lunit is a medical AI software company devoted to providing AI solutions for cancer diagnostics and therapeutics. With its deep learning technology, Lunit makes data-driven medicine the new standard of care. Lunit AI solutions help discover cancer and predict cancer treatment response by finding the right diagnosis at the right costs and the right treatment for the right patients.

Qritive Logo

Qritive is developing clinical-grade decision support systems to enhance histopathology diagnosis of cancer and to assist doctors in delivering insightful and personalized care to patients. The company has developed Pantheon, a CE marked vendor-agnostic digital pathology platform that enables digitization of the entire pathology lab workflow and telepathology, supports rich report generation, and provides a platform for AI analysis of pathology whole-slide images.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.